福布斯30位30岁以下亚洲人物榜公布 碳云智能两位合伙人同时入选

2016-03-02 佚名 生物谷

2016年2月25日《福布斯》杂志公布了一份"30位30岁以下亚洲人物榜"(Forbes 30 Under 30 Asia)。这是福布斯第一次由美国总部发起,以亚洲作为评选范围的评选的榜单,囊括了科学、媒体、娱乐等十个领域内30岁以下的创新者和领军人物。86年出生的碳云智能首席科学家李英睿入选生命科学榜,87年出生的媒体合伙人艾诚入选媒体市场榜。 碳云智能首席科学家 李英睿 简介: 2006年

2016年2月25日《福布斯》杂志公布了一份"30位30岁以下亚洲人物榜"(Forbes 30 Under 30 Asia)。这是福布斯第一次由美国总部发起,以亚洲作为评选范围的评选的榜单,囊括了科学、媒体、娱乐等十个领域内30岁以下的创新者和领军人物。86年出生的碳云智能首席科学家李英睿入选生命科学榜,87年出生的媒体合伙人艾诚入选媒体市场榜。

碳云智能首席科学家 李英睿 简介:

2006年加入华大基因,主导和参与人类基因组基础研究、复杂疾病和肿瘤研究的多项重大科研计划,任华大基因科技体系第一负责人。2012年起任华大科技首席执行官,2014年起任华大基因首席科学家,2015年受聘昆士兰大学荣誉教授,2015年成为碳云智能科技合伙人。

碳云智能媒体合伙人 艾诚 简介:

艾问传媒创始人,知名财经主持人。曾任中央电视台驻纽约财经评论员、世界银行华盛顿总部国际金融总公司投资顾问;多次受邀主持亚洲博鳌论坛、上海世博会、APEC等财智盛会,热衷公益和传媒政策研究。哈佛大学肯尼迪学院经济政策专业毕业,被世界经济论坛授予"全球杰出青年"称号。2015年成为碳云智能科技合伙人。

福布斯30位30岁以下亚洲名人榜(生命科学类):

http://www.forbes.com/30-under-30-asia-2016/healthcare-science/

福布斯30位30岁以下亚洲名人榜(媒体市场类):

http://www.forbes.com/30-under-30-asia-2016/media-marketing-advertising/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
    2018-03-16 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
    2016-03-03 1de6a4a6m46(暂无匿称)

    厉害

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
    2016-03-02 chenhui888

    佩服

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
    2016-03-02 破风4392

    厉害啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=296625, encodeId=a9262966253e, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Mar 16 05:08:32 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405416, encodeId=f568140541606, content=<a href='/topic/show?id=1960e467287' target=_blank style='color:#2F92EE;'>#福布斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74672, encryptionId=1960e467287, topicName=福布斯)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iauQrVAlcY8aEJHrvOlmLCVBwvib3FD7qTK78yugrQBRibZokBC8yjXErtdo83kC7EdJjDS1azWzoDnGkrHEroiaJA/132, createdBy=bcef2544989, createdName=zhaozhouchifen, createdTime=Fri Mar 04 04:45:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67107, encodeId=1d6e6e10728, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3131695284, createdName=1de6a4a6m46(暂无匿称), createdTime=Thu Mar 03 21:16:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66910, encodeId=de9c66910f2, content=佩服, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Mar 02 22:11:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66887, encodeId=55e86688ea3, content=厉害啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160301/IMG56D53216887587291.jpg, createdBy=3c131694128, createdName=破风4392, createdTime=Wed Mar 02 20:48:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66857, encodeId=9c516685eea, content=好厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Mar 02 18:45:00 CST 2016, time=2016-03-02, status=1, ipAttribution=)]
    2016-03-02 1de11f7fm56(暂无匿称)

    好厉害

    0

相关资讯

英国雄心勃勃打造150亿规模基因疗法、细胞疗法市场

基因疗法和细胞免疫疗法已经成为当今医药产业聚焦的焦点。这些新技术将对人类健康产生难以估量的影响。也正是由于这个原因,英国政府最近表示将扶植本国的细胞和基因疗法并预计这一领域的总产值将达到150亿美元之多。 而为了实现这一远大目标,英国政府及技术界人士也展开了广泛的讨论。其中热点之一就是目前正处于临床研究的T细胞疗法。来自英国Cell Therapy Catapult的Dr. Ward称越来越

比尔盖茨也青睐!芝加哥Exicure再获4200万美元研发资金

可能大多数人都没有听说过Exicure公司。与其他科技公司云集波士顿等地不同,这家原子西北大学的生物医药公司坐落于旧金山。但是千万不要认为它就是一个默默无闻之辈。不久前,公司刚刚完成了一项总额达4200万美元的融资,投资人中赫然包括了比尔盖茨在内的众多资深投资人和科技界大佬。尽管投资者无法确定Exicure公司一定会成功,但是至少公司已经向其展示了自身的实力和潜力。 公司致力于开发其独有的球

PTC杜氏营养肌不良症药物被拒

今天美国生物技术公司PTC Therapeutic的杜氏营养肌不良症(DMD)药物Translarna(ataluren)被FDA拒绝受理。Translarna已经在欧盟有条件上市,但如果三期临床失败仍可能被撤市。在去年的一个三期临床试验中Translarna未能显着改善DMD儿童6分钟走,但PTC认为亚组分析显示该药对部分病人可能有效。PTC前总经理说她不能肯定Translarn

盘点:CAR-T细胞疗法进展一览

CAR-T(Chimeric Antigen Receptor T-Cell Immunotherapy),即嵌合抗原受体T细胞免疫疗法。该疗法是一种出现了很多年但近几年才被改良使用到临床中的新型细胞疗法。在急性白血病和非霍奇金淋巴瘤的治疗上有着显著的疗效,被认为是最有前景的肿瘤治疗方式之一。正如所有的技术一样,CAR-T技术也经历一个漫长的演化过程,正是在这一系列的演化过程中,CAR-T技术

Nature:研究或帮助改善HIV疗法的开发

Nature上的一项最新研究中,来自明尼苏达大学等机构的科学家们开发了一种抵御HIV/AIDS及以反转录病毒为基础的癌症的新型治疗方法,文章中,研究者采用了一种利用固化分子X射线技术的实验性步骤进行研究,他们揭示了一种名为呼吸道合胞病毒(respiratory syncytial virus, RSV)的促癌反转录病毒如何集合多种蛋白(整合酶)拷贝从而形成小型分子,这种

Nature Biotechnol:基因治疗应用CRISPR/Cas9治疗肝脏疾病

在过去35年基因治疗发展进程中,James Wilson是其中一位开拓者,近期他把病毒载体和最新CRISPR/ Cas9技术结合,来应对罕见的遗传性肝病。他主要是针对啮齿类动物进行实验研究,该工作虽然给我们提供了新技术的希望,但也存在意想不到的障碍。 宾夕法尼亚州大学基因治疗研究所的教授James Wilson是腺相关病毒(AAV)载体制造之父,该载体主要应用于基因治疗。尽管早期一名病人死亡使基